AAFE - American Academy of Facial Esthetics
NOVEMBER 15, 2024
By Brigid Landrum, RN When it comes to enhancing your smile, the world of cosmetic procedures offers a variety of options to achieve your desired look. Two popular treatments that often come into play are lip fillers and lip flips. Both can help enhance the appearance of your lips, but they serve different purposes and are suitable for different needs.
MedEsthetics
NOVEMBER 15, 2024
We're diving into the "Ozempic Face" phenomenon to examine Ozempic's various effects on facial skin, what causes these side effects and separating the myths from the truth about its impact on facial aesthetics.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Lipgloss and Aftershave
NOVEMBER 15, 2024
Microneedling and nano infusion are powerful tools on their own, but together, they create a synergistic effect that can transform your clients’ skin. By incorporating one microneedling treatment every three months and supporting it with 3 – 4 nano infusion treatments in between, while using topicals with potent ingredients and a proven delivery system professionals provide a comprehensive treatment that delivers visible, long-lasting age management results.
Beauty Launchpad
NOVEMBER 15, 2024
Hairdustry is excited to announce the fifth annual Presley Poe and Friends event, set for April 26-27, 2025, in Frederick, Maryland. This year’s theme, “Tech Behind the Chair,” will showcase the latest innovations driving the future of hairstyling.
MedEsthetics
NOVEMBER 15, 2024
Supercharged with next-generation botanical extracts and proven barrier-rejuvenating ingredients, this mask enhances skin radiance for a visibly brighter, healthier complexion after just one use.
Beauty Launchpad
NOVEMBER 15, 2024
Hairdustry is excited to announce the fifth annual Presley Poe and Friends event, set for April 26-27, 2025, in Frederick, Maryland. This year’s theme, “Tech Behind the Chair,” will showcase the latest innovations driving the future of hairstyling.
Esthetician Leadership Today brings together the best content for skin care professionals from the widest variety of industry thought leaders.
The Dermatology Digest
NOVEMBER 15, 2024
The first subject has been dosed in the Phase III trial of the InnoCare Pharma’s novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332, for the treatment of atopic dermatitis (AD) in China. ICP-332 is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders, including AD and vitiligo.
Dermatology Times
NOVEMBER 15, 2024
Catch up on coverage from the third day of the 2024 Society of Dermatology Physician Associates Fall Conference in Las Vegas, Nevada.
The Dermatology Digest
NOVEMBER 15, 2024
The U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for dupilumab (Dupixent, Sanofi & Regeneron) to treat adults and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment.
Dermatology Times
NOVEMBER 15, 2024
Catch up on coverage from the second day of the 2024 Society of Dermatology Physician Associates Fall Conference in Las Vegas, Nevada.
Dermatology Times
NOVEMBER 15, 2024
At the 2024 SDPA Fall Conference, Sara Wilchowski, DMSc, MPAS, PA-C, highlighted the challenges and rewards of transitioning to industry roles, the impact of “Insta-Tok” on patient care, and the evolving landscape of dermatology.
Dermatology Times
NOVEMBER 15, 2024
SDPA President Amber Blair, PA-C, discusses new member opportunities and recognizes PA leaders.
Dermatology Times
NOVEMBER 15, 2024
A poster presented at the 2024 SDPA Fall Conference demonstrated that clascoterone cream remains stable when paired with commonly prescribed acne topicals, supporting its role in multimodal therapy.
Dermatology Times
NOVEMBER 15, 2024
Dermatology physician associates via DPAF conduct skin checks at the Sun Bus during Fall Conference.
Dermatology Times
NOVEMBER 15, 2024
The target action date for the FDA decision is April 18, 2025.
Dermatology Times
NOVEMBER 15, 2024
Panelists discuss common misconceptions about the mechanism of action of PDE4 inhibitors in clinical practice, emphasizing that not all PDE4 inhibitors are created equal and how these differences can significantly impact their efficacy and safety profiles.
Dermatology Times
NOVEMBER 15, 2024
Panelists discuss the current landscape of topical treatments for atopic dermatitis, focusing on the evolution of nonsteroidal options over the past decade, and explain the mechanism of action of PDE4 inhibitors in specifically targeting inflammatory pathways associated with the condition.
Dermatology Times
NOVEMBER 15, 2024
Michael Rubio, PA-C, previews the transformative programming and career-focused initiatives at this year’s Society of Dermatology Physician Associates Fall Conference in Las Vegas.
Dermatology Times
NOVEMBER 15, 2024
Panelists discuss how topical PDE4 inhibitors compare to traditional treatments like corticosteroids in terms of efficacy, safety, and long-term disease control, while also examining the unique formulations of roflumilast and crisaborole and their implications for skin penetration and patient experience; they highlight practical considerations for application, the management of adverse effects such as stinging and burning, and the distinct advantages of PDE4 inhibitors in addressing specific gap
Expert insights. Personalized for you.
60 
Let's personalize your content